M. Patrick Stagg

1.1k total citations
21 papers, 523 citations indexed

About

M. Patrick Stagg is a scholar working on Oncology, Surgery and Genetics. According to data from OpenAlex, M. Patrick Stagg has authored 21 papers receiving a total of 523 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 5 papers in Surgery and 5 papers in Genetics. Recurrent topics in M. Patrick Stagg's work include Colorectal Cancer Treatments and Studies (3 papers), Cancer Treatment and Pharmacology (3 papers) and Lung Cancer Research Studies (3 papers). M. Patrick Stagg is often cited by papers focused on Colorectal Cancer Treatments and Studies (3 papers), Cancer Treatment and Pharmacology (3 papers) and Lung Cancer Research Studies (3 papers). M. Patrick Stagg collaborates with scholars based in United States, Nigeria and Ireland. M. Patrick Stagg's co-authors include Hugh Mulcahy, Diarmuid P. O’Donoghue, Michael Jeffers, Mary Toner, Robert B. Diasio, Jean‐Pierre Sommadossi, E M Cretton, John D. Hainsworth, G A Omura and William R. Vogler and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

M. Patrick Stagg

19 papers receiving 507 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
M. Patrick Stagg United States 10 284 143 127 89 81 21 523
Giuseppe Colucci Italy 12 179 0.6× 82 0.6× 120 0.9× 91 1.0× 59 0.7× 28 548
Mauro Antimi Italy 10 273 1.0× 157 1.1× 303 2.4× 82 0.9× 51 0.6× 24 601
C. Varette France 10 436 1.5× 181 1.3× 189 1.5× 85 1.0× 88 1.1× 23 667
P Dufour France 8 385 1.4× 112 0.8× 103 0.8× 66 0.7× 71 0.9× 24 532
D. Braumann Germany 14 331 1.2× 165 1.2× 135 1.1× 63 0.7× 65 0.8× 28 568
Sujith Kalmadi United States 10 143 0.5× 106 0.7× 75 0.6× 52 0.6× 34 0.4× 26 427
Lance Sieger United States 9 166 0.6× 196 1.4× 129 1.0× 94 1.1× 56 0.7× 16 545
Isabelle Madelaine‐Chambrin France 12 387 1.4× 131 0.9× 33 0.3× 125 1.4× 147 1.8× 20 717
Michael S. Frontiera United States 7 335 1.2× 93 0.7× 88 0.7× 48 0.5× 100 1.2× 10 455
Anne‐Marie Maddox United States 10 469 1.7× 399 2.8× 50 0.4× 191 2.1× 50 0.6× 18 754

Countries citing papers authored by M. Patrick Stagg

Since Specialization
Citations

This map shows the geographic impact of M. Patrick Stagg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. Patrick Stagg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. Patrick Stagg more than expected).

Fields of papers citing papers by M. Patrick Stagg

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M. Patrick Stagg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. Patrick Stagg. The network helps show where M. Patrick Stagg may publish in the future.

Co-authorship network of co-authors of M. Patrick Stagg

This figure shows the co-authorship network connecting the top 25 collaborators of M. Patrick Stagg. A scholar is included among the top collaborators of M. Patrick Stagg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M. Patrick Stagg. M. Patrick Stagg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Saraf, Santosh L., Shehu U. Abdullahi, Modupe Idowu, et al.. (2025). Efficacy and safety of osivelotor in participants with sickle cell disease in a 12-week phase 2, multicenter, open-label, dose-finding trial and extension study. Blood. 146(Supplement 1). 4728–4728.
3.
Stagg, M. Patrick, Kimberly L. Drews, Philip R. Schauer, et al.. (2024). High prevalence of dysfunctional uterine bleeding in candidates for metabolic/bariatric surgery: increased endometrial cancer risk?. Surgery for Obesity and Related Diseases. 20(11). 1172–1178. 1 indexed citations
4.
Kundranda, Madappa N., et al.. (2021). Infection Masquerading as Recurrence of Pancreatic Ductal Adenocarcinoma: A Cautionary Tale. Cureus. 13(8). e17010–e17010. 1 indexed citations
5.
Stagg, M. Patrick, et al.. (2021). Management of Acquired Factor VIII Inhibitors With NovoSeven and Obizur. Cureus. 13(10). e19145–e19145. 2 indexed citations
6.
Stagg, M. Patrick, et al.. (2021). Salivary Duct Carcinoma: Case Reports and Brief Review of the Literature. SHILAP Revista de lepidopterología. 2021. 1–4. 1 indexed citations
7.
8.
Hughes, John, et al.. (2020). Ibrutinib-Associated Cardiac Tamponade with Concurrent Antiplatelet Therapy. SHILAP Revista de lepidopterología. 2020. 1–5. 7 indexed citations
9.
Spigel, David R., John D. Hainsworth, Jeffrey A. Sosman, et al.. (2005). Bevacizumab and erlotinib in the treatment of patients with metastatic renal carcinoma (RCC): Update of a phase II multicenter trial. Journal of Clinical Oncology. 23(16_suppl). 4540–4540. 27 indexed citations
10.
11.
12.
Rinaldi, David, et al.. (2000). A Phase I Trial of Gemcitabine and Infusional 5-Fluorouracil (5-FU) in Patients with Refractory Solid Tumors. American Journal of Clinical Oncology. 23(1). 78–82. 5 indexed citations
13.
Hainsworth, John D., Walter J. Urba, Jeremy K. Hon, et al.. (1998). One-hour paclitaxel plus carboplatin in the treatment of advanced non-small cell lung cancer: results of a multicentre, phase II trial. European Journal of Cancer. 34(5). 654–658. 37 indexed citations
14.
Stagg, M. Patrick, et al.. (1995). Long-term follow-up of a randomized post-induction therapy trial in acute myelogenous leukemia (a Southeastern Cancer Study Group trial).. PubMed. 9(9). 1456–60. 10 indexed citations
15.
Jeffers, Michael, et al.. (1994). The prognostic significance of immunohistochemically detected lymph node micrometastases in colorectal carcinoma. The Journal of Pathology. 172(2). 183–187. 203 indexed citations
16.
Vogler, William R., M. Patrick Stagg, A. A. Bartolucci, et al.. (1994). A phase III trial of high-dose cytosine arabinoside with or without etoposide in relapsed and refractory acute myelogenous leukemia. A Southeastern Cancer Study Group trial.. PubMed. 8(11). 1847–53. 54 indexed citations
17.
Stagg, M. Patrick, et al.. (1992). Clinical pharmacokinetics of 3′-azido-3′-deoxythymidine (zidovudine) and catabolites with formation of a toxic catabolite, 3′-amino-3′-deoxythymidine. Clinical Pharmacology & Therapeutics. 51(6). 668–676. 85 indexed citations
18.
Stagg, M. Patrick & Robert B. Diasio. (1990). Novel chemotherapeutic agents in early clinical development. Current Opinion in Oncology. 2(6). 1119–1125. 2 indexed citations
19.
Stagg, M. Patrick, et al.. (1989). Mixed essential cryoglobulinemia and adult respiratory distress syndrome: a case report. The American Journal of Medicine. 87(4). 445–448. 14 indexed citations
20.
Stagg, M. Patrick, et al.. (1987). Chronic lymphocytic leukemic meningitis as a cause of the syndrome of inappropriate secretion of antidiuretic hormone. Cancer. 60(2). 191–192. 24 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Giuseppe Colucci Breakdown of academic impact, for papers by Mauro Antimi Breakdown of academic impact, for papers by C. Varette Breakdown of academic impact, for papers by P Dufour Breakdown of academic impact, for papers by D. Braumann Breakdown of academic impact, for papers by Sujith Kalmadi Breakdown of academic impact, for papers by Lance Sieger Breakdown of academic impact, for papers by Isabelle Madelaine‐Chambrin Breakdown of academic impact, for papers by Michael S. Frontiera Breakdown of academic impact, for papers by Anne‐Marie Maddox
Rankless by CCL
2026